2023
A computational model for learning from repeated traumatic experiences under uncertainty
Kaye A, Rao M, Kwan A, Ressler K, Krystal J. A computational model for learning from repeated traumatic experiences under uncertainty. Cognitive, Affective, & Behavioral Neuroscience 2023, 23: 894-904. PMID: 37165181, PMCID: PMC11149767, DOI: 10.3758/s13415-023-01085-5.Peer-Reviewed Original ResearchPosttraumatic stress disorderTraumatic eventsNovel contextThreat perceptionTreatment of PTSDEarly life traumaNeutral cuesThreat responsesStress disorderLife traumaTraumatic experiencesPrediction errorComputational theorySensory cuesPTSD incidenceNovel predictionsUnpredictable footshockInternal statesComputational modelCuesPerceptionSpecific associationFootshockContextTheory
2018
The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder
Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL, Gomaa H, Adikey A, Krystal JH. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. The Annual Review Of Pharmacology And Toxicology 2018, 59: 171-189. PMID: 30216745, PMCID: PMC6326888, DOI: 10.1146/annurev-pharmtox-010818-021701.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStress disorderTreatment of PTSDBiology of PTSDExert complex effectsBrain functionNeurobiologySynaptic gainPathology modelRapid-acting antidepressantsBroader frameworkDisordersWordsPutative mechanismsDysconnectivitySynaptic lossPharmacotherapeutic optionsClinical efficacyCompelling efficacyPerspectiveAntidepressantsDrug developmentComplex effectsPathologyEfficacy
2017
Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology
Kelmendi B, Adams TG, Southwick S, Abdallah CG, Krystal JH. Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology. Clinical Psychology Science And Practice 2017, 24: 281-297. PMID: 31404451, PMCID: PMC6688474, DOI: 10.1111/cpsp.12202.Peer-Reviewed Original ResearchSynaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports 2017, 19: 74. PMID: 28844076, PMCID: PMC5904792, DOI: 10.1007/s11920-017-0829-z.Peer-Reviewed Original ResearchConceptsSynaptic connectivityRapid-acting treatmentPathophysiology of PTSDPotential clinical importanceTreatment of PTSDSynaptic lossPurpose of ReviewStudiesDisconnection syndromeClinical importanceNovel pharmacotherapeuticsNovel therapeuticsPTSD symptomsRecent FindingsHerePTSDPathophysiologyKetamineTreatmentDisordersTherapeutic applicationsStress-related lossesSyndromeSymptomsPharmacotherapeuticsAltered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence
Holmes SE, Girgenti MJ, Davis MT, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Southwick S, Duman RS, Carson RE, Krystal JH, Esterlis I, Friedman M, Kowall N, Brady C, McKee A, Stein T, Huber B, Kaloupek D, Alvarez V, Benedek D, Ursano R, Williamson D, Cruz D, Young K, Duman R, Krystal J, Mash D, Hardegree M, Serlin G. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 8390-8395. PMID: 28716937, PMCID: PMC5547601, DOI: 10.1073/pnas.1701749114.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderMGluR5 availabilityPositron emission tomographyGlutamate systemMetabotropic glutamate receptor 5Treatment of PTSDHuman posttraumatic stress disorderGlutamate receptor 5Mechanism-based treatmentsExpression of FKBP5Promising treatment targetHuman postmortem tissueTargeted pharmacological treatmentStress psychopathologyPharmacological treatmentExpression of proteinsReceptor 5MGluR5Treatment targetsPostmortem tissueEmission tomographyStress disorderPostmortem samplesPromising targetDisorders
2011
Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence
Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH. Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. Neuropsychopharmacology 2011, 37: 996-1004. PMID: 22089316, PMCID: PMC3280636, DOI: 10.1038/npp.2011.283.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderSerotonin uptake inhibitorNorepinephrine uptake inhibitorUptake inhibitorAlcohol dependenceMale veteransTreatment of PTSDUse outcomesSymptoms of PTSDDouble-blind conditionsMain outcome measuresEvidence of efficacyComorbid alcohol dependenceCurrent diagnostic criteriaAlcohol use disorderAlcohol use outcomesComorbid conditionsAdjunctive efficacyOutcome measuresOnly FDADiagnostic criteriaUse disordersClinical advantagesAlcohol consumptionDrug Administration